MERGE microbial strain improvement technique

MERGE uses non-GMO techniques to turn probiotics into therapeutics and reliable, commercial strains

MERGE is a patented strain improvement technique which used a type of directed evolution resulting in new phenotypes and antimicrobials. It turns mediocre results into repeatable and reliable results.

SciBac has used MERGE to create 2 novel lung therapeutics with multiple mechanisms designed to clear chronic lung infections in cystic fibrosis.

Technology:
  • Infection prevention
  • Antimicrobial stewardship
  • Alternative antimicrobials

Microorganisms:
  • Bacteria
  • Fungi
  • Yeasts
  • Parasites

Application:
  • Human
  • Veterinary
  • AgriFood
  • Environmental

Development stage:
  • Research
  • Development
  • Validation

Organization:
  • Company

Partnering:
  • License, Co-develop, Joint Venture, Sell

We are looking for partners to develop our lung therapeutics or to make novel ones with MERGE.

We are a pre-clinical, biotech start-up. We have raised $2M and looking for additional revenue through out-licensing as well as angel investments.

SciBac is open to improving existing biotherapeutics or creating new ones. We can use our technology to go after AMR anywhere there is a microbiome, so skin, uro-genital, lung, mouth, and gastro-intestinal applications can all be addressed.


What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!